TwinBeech Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.95M Buy
+52,556
New +$3.12M 0.46% 64
2025
Q2
– Sell
-6,445
Closed -$216K – 1017
2025
Q1
$216K Buy
+6,445
New +$245K ﹤0.01% 652
2024
Q3
– Sell
-88,711
Closed -$3.46M – 932
2024
Q2
$3.46M Sell
88,711
-9,331
-10% -$373K 0.07% 264
2024
Q1
$4.22M Buy
+98,042
New +$4.51M 0.09% 239
2023
Q1
– Sell
-101,717
Closed -$4.01M – 928
2022
Q4
$4.01M Buy
101,717
+52,967
+109% +$1.93M 0.08% 302
2022
Q3
$1.76M Buy
48,750
+37,727
+342% +$1.36M 0.05% 359
2022
Q2
$335K Sell
11,023
-16,445
-60% -$497K 0.02% 447
2022
Q1
$840K Buy
27,468
+20,590
+299% +$616K 0.04% 338
2021
Q4
$215K Buy
+6,878
New +$206K 0.01% 513

Other funds holding XENE

TwinBeech Capital's XENE Position: Q3 2026 in Review

TwinBeech Capital opened a new position in Xenon Pharmaceuticals (XENE) in Q3 2026: 52,556 shares worth $1.95M. The stake represents 0.46% of the portfolio and ranks #64 among its holdings. This is a return to the name: TwinBeech Capital previously reported a position in XENE as recently as Q1 2025.

TwinBeech Capital first reported a position in XENE in Q4 2021 and has held it in 9 quarters since. The position peaked at $4.22M in Q1 2024. 286 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • TwinBeech Capital held 52,556 shares of Xenon Pharmaceuticals worth $1.95M as of Q3 2026.
  • Xenon Pharmaceuticals was a new TwinBeech Capital position in Q3 2026.
  • Xenon Pharmaceuticals made up 0.46% of TwinBeech Capital's portfolio in Q3 2026, its #64 holding.
  • TwinBeech Capital first reported a position in Xenon Pharmaceuticals in Q4 2021 and has held it in 9 quarters since.
  • TwinBeech Capital's Xenon Pharmaceuticals position peaked at $4.22M in Q1 2024.
  • 286 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on TwinBeech Capital's 13F filing for Q3 2026, filed 16 Nov 2026.